|
|
|
|
|||||
|
|
|
Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Passive Income Stocks to Buy Right Now.
![Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 12, Scotiabank’s Louise Chen began coverage of ten large-cap biopharma companies and took a positive stance on the sector, noting that years of lagging performance compared with other industries and major indices may offer investors an appealing entry point, according to a report by The Fly. She suggested that the next phase of innovation could be driven by companies working toward actual cures for serious illnesses. In her view, firms that are positioned to be first in treating diseases with the aim to cure them stand out. She pointed to Johnson & Johnson (NYSE:JNJ) as the firm’s top pick, saying the company’s work toward curative treatments and its consistent execution are making its underlying growth clearer. Scotiabank kept an Outperform rating on the stock. Johnson & Johnson (NYSE:JNJ) carries a dividend record that is rarely matched. It has raised its payout for 63 straight years. Even with challenges such as patent expirations, the company’s broad pharmaceutical portfolio continues to produce steady growth. This year it faced the loss of US exclusivity for Stelara, a major immunology drug, yet both revenue and earnings continued to trend higher. Third-quarter sales reached $24 billion, up 6.8% from the same period last year. Johnson & Johnson (NYSE:JNJ) operates globally and focuses on two main areas: Innovative Medicine and MedTech. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. [im-promo] While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has a 100x upside potential, check out our report about the cheapest AI stock. [/im-promo] READ NEXT: 15 Best Dividend Growth Stocks to Buy Now and 15 Overlooked Dividend Stocks to Buy Right Now Disclosure: None.](https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/19171751/JNJ-insidermonkey-1695158269091.jpg)
On November 12, Scotiabank’s Louise Chen began coverage of ten large-cap biopharma companies and took a positive stance on the sector, noting that years of lagging performance compared with other industries and major indices may offer investors an appealing entry point, according to a report by The Fly. She suggested that the next phase of innovation could be driven by companies working toward actual cures for serious illnesses.
In her view, firms that are positioned to be first in treating diseases with the aim to cure them stand out. She pointed to Johnson & Johnson (NYSE:JNJ) as the firm’s top pick, saying the company’s work toward curative treatments and its consistent execution are making its underlying growth clearer. Scotiabank kept an Outperform rating on the stock.
Johnson & Johnson (NYSE:JNJ) carries a dividend record that is rarely matched. It has raised its payout for 63 straight years. Even with challenges such as patent expirations, the company’s broad pharmaceutical portfolio continues to produce steady growth. This year it faced the loss of US exclusivity for Stelara, a major immunology drug, yet both revenue and earnings continued to trend higher. Third-quarter sales reached $24 billion, up 6.8% from the same period last year.
Johnson & Johnson (NYSE:JNJ) operates globally and focuses on two main areas: Innovative Medicine and MedTech.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Extreme Dividend Stocks to Buy According to Hedge Funds and 15 Overlooked Dividend Stocks to Buy Right Now.
Disclosure: None.
| Nov-15 | |
| Nov-14 | |
| Nov-14 | |
| Nov-14 | |
| Nov-14 | |
| Nov-14 | |
| Nov-13 | |
| Nov-13 | |
| Nov-13 | |
| Nov-13 | |
| Nov-13 | |
| Nov-13 | |
| Nov-13 | |
| Nov-12 |
BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie
JNJ
Investor's Business Daily
|
| Nov-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite